<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242216</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-03-315</org_study_id>
    <nct_id>NCT00242216</nct_id>
  </id_info>
  <brief_title>&quot;The Once A Day Protease Inhibitor Regimens&quot;</brief_title>
  <official_title>&quot;PIQD: The Once a Day Protease Inhibitor Regimens.&quot; Ritonavir Boosted Atazanavir vs. Ritonavir Boosted Fosamprenavir Used in Combination With Tenofovir and Emtricitabine in HIV-1 Infected Antiretroviral Treatment-Naïve Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atazanavir (ATV) and fosamprenavir (fAPV) are new protease inhibitors that can be
      administered once-a-day and boosted with ritonavir (r). Prior studies have demonstrated that
      both are effective in treatment of ARV-naïve HIV-infected people. This study was designed to
      demonstrate if a HAART regimen containing ATV/r is not inferior to a HAART regimen containing
      fAPV/r, in ARV-naïve patients over a 96-week period.

      This is a phase IV, single center, randomized, open label, 2-arm clinical trial in ARV
      therapy-naïve patients with HIV-1 RNA &gt;1,000 copes/mL and CD4 cell count &lt;350 cells/mm3.
      Patients will be randomized to receive tenofovir and emtricitabine plus either ATV (300mg qd)
      and ritonavir (100mg qd) or fAPV (1400mg qd) and ritonavir (200mg qd).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the past decade, there have been significant advances toward fighting the progression of
      HIV disease. Current treatment strategies consist of utilization of potent combination
      antiretroviral therapy to suppress HIV replication below detectable limits limiting the
      potential for the emergence of resistant viruses, boosting CD4 cell counts and thereby
      delaying disease progression. Treatment of HIV-1 infection with Highly Active Antiretroviral
      Therapy (HAART) regimens containing a protease inhibitor (PI) and two nucleoside reverse
      transcriptase inhibitor (NRTIs) has been shown to prolong survival and decrease disease
      progression. Despite these potent antiretroviral agents, current available therapies continue
      to fail in some patients. Poor adherence to complex treatment regimens remains a significant
      cause of suboptimal viral suppression leading to emerge of resistant virus. Atazanavir and
      fosamprenavir were recently FDA approved protease inhibitors. The efficacy and safety profile
      of these two drugs have been established in clinical trials enrolling antiretroviral therapy
      naïve and protease inhibitor experienced patients. Atazanavir and fosamprenavir are the only
      protease inhibitors approved for a once a day regimen and this may set a new standard for
      treatment of antiretroviral therapy naïve HIV infected patients. Adherence to the medicines,
      a key component of treatment success, could be significantly improved by using these once
      daily regimens. However, no head-to-head trials comparing the safety and efficacy of
      fosamprenavir and atazanavir have been published. This prospective, randomized, open label
      2-arm study will compare these two protease inhibitors for therapy of antiretroviral
      treatment-naïve HIV-infected patients. Patients who are successfully screened for eligibility
      will be randomized to receive tenofovir and emtricitabine plus either atazanavir (300mg qd)
      and ritonavir (100mg qd) or fosamprenavir (1400mg qd) and ritonavir (200mg qd). Participants
      will undergo assessment on day 1 and attend study visits at weeks 6, 12 and every 3 months
      until the completion of the study on week 96. &quot;Antiretroviral Medication Self-Report&quot; and
      &quot;3-Day HIV Medication Self-Report&quot; questionnaires will be applied at weeks 6, 12 and every 3
      month, thereafter, until week 96. &quot;Changes in Body Appearance&quot; questionnaire will be applied
      at baseline and weeks 24, 48, 72, and 96.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patient With Viral Load Less Than 400 Copies/mL</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4 Cell Count Change From Baseline During Treatment.</measure>
    <time_frame>24 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Atazanavir oral once daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HIV treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosamprenavir oral once daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HIV treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir-boosted atazanavir</intervention_name>
    <description>100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.</description>
    <arm_group_label>Atazanavir oral once daily</arm_group_label>
    <other_name>Reyataz plus Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir-boosted fosamprenavir</intervention_name>
    <description>100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.</description>
    <arm_group_label>Fosamprenavir oral once daily</arm_group_label>
    <other_name>Lexiva plus Norvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older.

          -  Patient agrees to participate in the study by giving written informed consent.

          -  Documentation of HIV infection.

          -  No prior treatment with any anti-retroviral agent.

          -  CD4 cell count &lt; 350 cells x mm3 or with an AIDS defining condition.

          -  Viral load &gt; 1,000 copies/mL

        Exclusion Criteria:

          -  Less than 18 years old.

          -  Current pregnancy or breastfeeding.

          -  Any previous antiretroviral regimen.

          -  Severe hepatic impairment that precludes the use of either study drug. This will be
             defined as any laboratory value of Grade 3 or 4 on the ACTG scale.

          -  Use of any contra-indicated medication as defined in the package insert for each drug.

          -  Any condition that, in the judgment of the investigator, precludes successful
             participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto C Arduino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Street Health Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher T, Giordano M. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003 Dec 5;17(18):2603-14.</citation>
    <PMID>14685054</PMID>
  </reference>
  <reference>
    <citation>Sax PE. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients. AIDS Clin Care. 2003 Sep;15(9):78.</citation>
    <PMID>14666914</PMID>
  </reference>
  <reference>
    <citation>Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506.</citation>
    <PMID>12949633</PMID>
  </reference>
  <reference>
    <citation>Goldsmith DR, Perry CM. Atazanavir. Drugs. 2003;63(16):1679-93; discussion 1694-5. Review.</citation>
    <PMID>12904086</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):22-32.</citation>
    <PMID>14707788</PMID>
  </reference>
  <reference>
    <citation>SOLO trial results released. AIDS Patient Care STDS. 2003 Feb;17(2):95.</citation>
    <PMID>12639292</PMID>
  </reference>
  <reference>
    <citation>Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, Prince WT. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002 Aug;42(8):887-98.</citation>
    <PMID>12162471</PMID>
  </reference>
  <reference>
    <citation>Vierling P, Greiner J. Prodrugs of HIV protease inhibitors. Curr Pharm Des. 2003;9(22):1755-70. Review.</citation>
    <PMID>12871195</PMID>
  </reference>
  <reference>
    <citation>Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, Friedland G; Terry Beirn Community Programs for Clinical Research on AIDS. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005 Jan;17(1):10-22.</citation>
    <PMID>15832830</PMID>
  </reference>
  <results_reference>
    <citation>Holmes A, Lucke J, Maghidman S, Fernandez-Bussy S, Barnett B, Arduino R. Tenofovir associated nephrotoxicity is dose-dependent ritonavir administration a co-factor? XVI International AIDS Conference. Toronto, Canada. August 13-18, 2006. Abstract TUPE0085.</citation>
  </results_reference>
  <results_reference>
    <citation>Bell TK, Holmes A, McCormack OE, Barnett BJ, Arduino RC. Changing Genotypic Resistance Patterns and Demographics of Antiretroviral-Naïve HIV Patients in Houston: 1999-2006. 44th Annual Meeting of the Infectious Diseases Society of America (IDSA). Toronto, Canada. October 12-15, 2006. Abstract 975.</citation>
  </results_reference>
  <results_reference>
    <citation>Holmes A, Bell T, Barnett B, Arduino R. Emerging resistance mutations in once-daily ritonavir-boosted protease inhibitor-containing antiretroviral regimens. 44th Annual Meeting of the Infectious Diseases Society of America (IDSA). Toronto, Canada. October 12-15, 2006. Abstract 973.</citation>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2005</study_first_submitted>
  <study_first_submitted_qc>October 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2005</study_first_posted>
  <results_first_submitted>May 2, 2013</results_first_submitted>
  <results_first_submitted_qc>August 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2013</results_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Roberto Arduino</investigator_full_name>
    <investigator_title>Professor - Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV-1 infected people</keyword>
  <keyword>Antiretroviral treatment-naïve</keyword>
  <keyword>Atazanavir</keyword>
  <keyword>Fosamprenavir</keyword>
  <keyword>ARV Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients enrolled at a county clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Atazanavir</title>
          <description>Atazanavir/ritonavir (300mg/100mg) once daily</description>
        </group>
        <group group_id="P2">
          <title>Fosamprenavir</title>
          <description>Fosamprenavir/ritonavir (1400mg/100mg) once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no medicaiton dispensed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atazanavir</title>
        </group>
        <group group_id="B2">
          <title>Fosamprenavir</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="9.7"/>
                    <measurement group_id="B2" value="48" spread="10"/>
                    <measurement group_id="B3" value="48" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patient With Viral Load Less Than 400 Copies/mL</title>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir</title>
          </group>
          <group group_id="O2">
            <title>Fosamprenavir</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patient With Viral Load Less Than 400 Copies/mL</title>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Cell Count Change From Baseline During Treatment.</title>
        <time_frame>24 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir</title>
          </group>
          <group group_id="O2">
            <title>Fosamprenavir</title>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count Change From Baseline During Treatment.</title>
          <units>cell/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" spread="119"/>
                    <measurement group_id="O2" value="117" spread="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atazanavir</title>
        </group>
        <group group_id="E2">
          <title>Fosamprenavir</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Left perineal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cryptococal meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure Disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Intracraneal Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Rupture hemorrhagic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Steven's Johnson Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>hyperbilirrubinemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased LFTs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>High porportion of subject did not complete the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Roberto C. Arduino, Professor of Medicine</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>713-500-6731</phone>
      <email>roberto.c.arduino@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

